C12N 2710/24234
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/24234 (Use of virus or viral component as vaccine) appears on 8 US grants and 13 published applications in this corpus.
Search patents in C12N- Granted patents
- 8
- Published applications
- 13
- Assignees
- 6
- Inventors
- 26
- Latest grant
- 25 May 2021
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 2 |
| 2004 | 3 | 3 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 1 | 1 |
| 2014 | 1 | 1 |
| 2015 | 0 | 0 |
| 2016 | 0 | 1 |
| 2017 | 1 | 1 |
| 2018 | 0 | 0 |
| 2019 | 0 | 1 |
| 2020 | 0 | 2 |
| 2021 | 1 | 0 |
| 2022 | 0 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Orf virus-based platform for vaccine delivery25 May 2021US 11,013,798 B2Federal University of Santa Maria
- Recombinant proteins of parapdxvirus ovis and pharmaceutical compositions therefrom25 Jul 2017US 9,714,272 B2AiCuris GmbH & Co. KG
- Recombinant proteins of Parapoxvirus ovis and pharmaceutical compositions therefrom7 Oct 2014US 8,852,577 B2AiCuris GmbH & Co. KG
- Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom22 Jan 2013US 8,357,363 B2AiCuris GmbH & Co. KG
- Nucleic acid and polypeptide sequences useful as adjuvants22 Jun 2004US 6,752,995 B2Board of Regents, The University of Texas System
- Parapoxvirus for conditioning for and treatment of coronavirus infections22 Dec 2022US 2022/0401553 A1AiCuris GmbH & Co. KG
- Combination Therapies of Hepatitis B Virus (HBV)-infected individuals using Parapoxvirus Ovis (PPVO) and at Least one Further Antiviral Drug20 Aug 2020US 2020/0261520 A1AiCuris GmbH & Co. KG
- Orf virus-based platform for vaccine delivery18 Jun 2020US 2020/0188509 A1Federal University of Santa Maria
- Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom26 Sep 2019US 2019/0292231 A1AiCuris GmbH & Co. KG
- Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom9 Nov 2017US 2017/0320918 A1AiCuris GmbH & Co. KG
Most cited
By later US patents
- Nucleic acid and polypeptide sequences useful as adjuvants24US 6,752,995 B2Board of Regents, The University of Texas System · 2004
- Process for the preparation of inducers of non-specific immunity and product produced5US 5,094,850 ABayer Aktiengesellschaft · 1992
- Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom3US 8,357,363 B2AiCuris GmbH & Co. KG · 2013